SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
VaccinesInfectious Disease

PUBLISHER: Market Glass, Inc. | PRODUCT CODE: 2148433

Cover Image

PUBLISHER: Market Glass, Inc. | PRODUCT CODE: 2148433

H1N1 Vaccines

PUBLISHED:
PAGES: 325 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF & Excel (Single User License)
USD 5850
PDF & Excel (Team License: Up to 10 users)
USD 11115
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries)
USD 17550

Add to Cart

Description

Table of Contents

Global H1N1 Vaccines Market to Reach US$2.9 Million by 2032

The global market for H1N1 Vaccines estimated at US$2.1 Million in the year 2025, is expected to reach US$2.9 Million by 2032, growing at a CAGR of 5.0% over the analysis period 2025-2032. Inactivated Vaccine Product Type, one of the segments analyzed in the report, is expected to record a 5.9% CAGR and reach US$2.0 Million by the end of the analysis period. Growth in the Live Attenuated Vaccine Product Type segment is estimated at 3.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$561.3 Thousand While China is Forecast to Grow at 8.8% CAGR

The H1N1 Vaccines market in the U.S. is estimated at US$561.3 Thousand in the year 2025. China, the world's second largest economy, is forecast to reach a projected market size of US$623.7 Thousand by the year 2032 trailing a CAGR of 8.8% over the analysis period 2025-2032. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.2% and 4.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.1% CAGR.

H1N1 Vaccines - Key Trends and Drivers

H1N1 vaccines are critical in preventing the spread of the H1N1 influenza virus, commonly known as swine flu. The H1N1 virus first emerged in 2009, causing a global pandemic that highlighted the need for effective vaccination strategies. These vaccines are developed using various methods, including inactivated (killed) virus, live attenuated (weakened) virus, and recombinant technologies. They are designed to stimulate the immune system to recognize and combat the H1N1 virus, thereby reducing the severity and incidence of the disease. Annual vaccination campaigns, particularly during flu season, play a crucial role in public health initiatives, targeting high-risk groups such as children, the elderly, pregnant women, and individuals with underlying health conditions. The ongoing evolution of the virus necessitates continuous updates and improvements in vaccine formulations to ensure their effectiveness against new strains.

Technological advancements have significantly enhanced the development, production, and distribution of H1N1 vaccines. Modern manufacturing techniques, including cell-based and recombinant DNA technologies, have improved the efficiency and speed of vaccine production. These methods allow for rapid scalability in response to outbreaks, ensuring sufficient supply to meet global demand. Additionally, advancements in adjuvant technology, which are substances added to vaccines to boost the immune response, have improved the efficacy of H1N1 vaccines. Enhanced surveillance systems and global collaboration among health organizations facilitate the timely identification of viral mutations, enabling the development of updated vaccines. Moreover, the integration of digital health tools, such as electronic health records (EHRs) and mobile health apps, supports effective monitoring and management of vaccination programs, ensuring higher coverage rates and better tracking of vaccine efficacy.

The growth in the H1N1 vaccines market is driven by several factors, including increasing awareness of the importance of vaccination, government initiatives and funding, and technological advancements in vaccine development. Public health campaigns emphasizing the benefits of vaccination have significantly increased vaccine uptake. Government programs and policies that provide funding and resources for vaccine research, development, and distribution also play a pivotal role in market growth. Technological advancements in biotechnology and immunology have led to the development of more effective and safer vaccines. Additionally, the rising prevalence of influenza outbreaks and the continuous mutation of the H1N1 virus drive the need for ongoing vaccination efforts. Collaboration between pharmaceutical companies and research institutions accelerates the innovation and availability of vaccines. The expansion of global healthcare infrastructure and improvements in cold chain logistics further support the widespread distribution and accessibility of H1N1 vaccines. Overall, these factors collectively contribute to the robust growth and development of the H1N1 vaccines market.

SCOPE OF STUDY:

The report analyzes the H1N1 Vaccines market by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Inactivated Vaccine Product Type, Live Attenuated Vaccine Product Type); Technology (Egg-based Technology, Cell-based Technology, Other Technologies); Administration Route (Intradermal Administration Route, Other Administration Routes); Age Group (Pediatric Age Group, Adult Age Group, Geriatric Age Group)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

SELECT PLAYERS -

  • Abbott Laboratories, Inc.
  • Baxter International, Inc.
  • Cipla Ltd.
  • GlaxoSmithKline PLC
  • Hualan Biological Engineering, Inc.
  • Merck & Co., Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Pfizer, Inc.
  • Sanofi
  • Sinovac Biotech Ltd.

WHAT SETS THIS REPORT APART FROM OTHERS?

Grounded in Domain Expert Perspectives - Incorporates perspectives emerging from domain experts across industry, enterprise and academia, adding context beyond conventional published research.

Captures Early Market Signals - Tracks shifts emerging through expert conversations, company activity and market-relevant discussions before they are fully reflected in traditional secondary research.

Draws From a Broad, Validated Intelligence Base - Brings together insights from conference sessions, keynotes, panel discussions, blogs, corporate disclosures, annual reports, institutional publications and other validated sources.

Connects Signals With Strategic Market Direction - Synthesizes these perspectives to identify where the market is moving, what is driving that movement and which developments are likely to matter most for strategy.

Provides In-Depth Company Intelligence - Extends beyond market-level analysis to examine the companies participating in and shaping the competitive environment.

Market Share Is Examined Where It Matters - A single global market share figure rarely tells the full story. Competitive structures can vary significantly across geographies. Where analytically relevant, Market Glass reports extend market share analysis into major regions with the level of detail tailored to the structure and dynamics of each market.

Show more
Product Code: MG6274

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy
    • Global Economic Update
    • H1N1 Vaccines - Global Key Competitors Percentage Market Share in 2026 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for 33 Players Worldwide in 2026 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Awareness of Vaccination Importance Throws the Spotlight on H1N1 Vaccines
    • Government Initiatives and Funding Propel Growth in Vaccine Research and Development
    • Technological Advancements in Biotechnology Expands Addressable Market Opportunity
    • Enhanced Surveillance Systems Strengthens Business Case for Timely Vaccine Updates
    • Integration of Adjuvant Technology Generates Demand for More Effective Vaccines
    • Development of Cell-Based and Recombinant DNA Technologies Drives Adoption of Modern Manufacturing Methods
    • Increasing Influenza Outbreaks and Viral Mutations Accelerates Demand for H1N1 Vaccines
    • Digital Health Tools and EHRs Spur Growth in Vaccination Program Management
    • Improvements in Cold Chain Logistics Sustains Growth in Vaccine Accessibility
    • Public Health Campaigns and Education Programs Generates Awareness and Vaccine Uptake
    • Ongoing Research in Immunology and Virology Expands Addressable Market Opportunity for Advanced Vaccines
    • Impact of Seasonal Variability on Vaccination Needs
    • Safety and Efficacy Improvements in Vaccine Formulations Drives Adoption of New Vaccines
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World H1N1 Vaccines Market Analysis of Annual Sales in US$ Thousand for Years 2020 through 2032
    • TABLE 2: World Recent Past, Current & Future Analysis for H1N1 Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
    • TABLE 3: World 8-Year Perspective for H1N1 Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2026 & 2032
    • TABLE 4: World Recent Past, Current & Future Analysis for Inactivated Vaccine Product Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
    • TABLE 5: World 8-Year Perspective for Inactivated Vaccine Product Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2026 & 2032
    • TABLE 6: World Recent Past, Current & Future Analysis for Live Attenuated Vaccine Product Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
    • TABLE 7: World 8-Year Perspective for Live Attenuated Vaccine Product Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2026 & 2032
    • TABLE 8: World Recent Past, Current & Future Analysis for Egg-based Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
    • TABLE 9: World 8-Year Perspective for Egg-based Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2026 & 2032
    • TABLE 10: World Recent Past, Current & Future Analysis for Cell-based Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
    • TABLE 11: World 8-Year Perspective for Cell-based Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2026 & 2032
    • TABLE 12: World Recent Past, Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
    • TABLE 13: World 8-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2026 & 2032
    • TABLE 14: World Recent Past, Current & Future Analysis for Intradermal Administration Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
    • TABLE 15: World 8-Year Perspective for Intradermal Administration Route by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2026 & 2032
    • TABLE 16: World Recent Past, Current & Future Analysis for Other Administration Routes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
    • TABLE 17: World 8-Year Perspective for Other Administration Routes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2026 & 2032
    • TABLE 18: World Recent Past, Current & Future Analysis for Pediatric Age Group by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
    • TABLE 19: World 8-Year Perspective for Pediatric Age Group by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2026 & 2032
    • TABLE 20: World Recent Past, Current & Future Analysis for Adult Age Group by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
    • TABLE 21: World 8-Year Perspective for Adult Age Group by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2026 & 2032
    • TABLE 22: World Recent Past, Current & Future Analysis for Geriatric Age Group by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
    • TABLE 23: World 8-Year Perspective for Geriatric Age Group by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2026 & 2032

III. MARKET ANALYSIS

  • UNITED STATES
    • H1N1 Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2026 (E)
    • TABLE 24: USA Recent Past, Current & Future Analysis for H1N1 Vaccines by Product Type - Inactivated Vaccine Product Type and Live Attenuated Vaccine Product Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 25: USA 8-Year Perspective for H1N1 Vaccines by Product Type - Percentage Breakdown of Value Sales for Inactivated Vaccine Product Type and Live Attenuated Vaccine Product Type for the Years 2026 & 2032
    • TABLE 26: USA Recent Past, Current & Future Analysis for H1N1 Vaccines by Technology - Egg-based Technology, Cell-based Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 27: USA 8-Year Perspective for H1N1 Vaccines by Technology - Percentage Breakdown of Value Sales for Egg-based Technology, Cell-based Technology and Other Technologies for the Years 2026 & 2032
    • TABLE 28: USA Recent Past, Current & Future Analysis for H1N1 Vaccines by Administration Route - Intradermal Administration Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 29: USA 8-Year Perspective for H1N1 Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intradermal Administration Route and Other Administration Routes for the Years 2026 & 2032
    • TABLE 30: USA Recent Past, Current & Future Analysis for H1N1 Vaccines by Age Group - Pediatric Age Group, Adult Age Group and Geriatric Age Group - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 31: USA 8-Year Perspective for H1N1 Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group, Adult Age Group and Geriatric Age Group for the Years 2026 & 2032
  • CANADA
    • TABLE 32: Canada Recent Past, Current & Future Analysis for H1N1 Vaccines by Product Type - Inactivated Vaccine Product Type and Live Attenuated Vaccine Product Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 33: Canada 8-Year Perspective for H1N1 Vaccines by Product Type - Percentage Breakdown of Value Sales for Inactivated Vaccine Product Type and Live Attenuated Vaccine Product Type for the Years 2026 & 2032
    • TABLE 34: Canada Recent Past, Current & Future Analysis for H1N1 Vaccines by Technology - Egg-based Technology, Cell-based Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 35: Canada 8-Year Perspective for H1N1 Vaccines by Technology - Percentage Breakdown of Value Sales for Egg-based Technology, Cell-based Technology and Other Technologies for the Years 2026 & 2032
    • TABLE 36: Canada Recent Past, Current & Future Analysis for H1N1 Vaccines by Administration Route - Intradermal Administration Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 37: Canada 8-Year Perspective for H1N1 Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intradermal Administration Route and Other Administration Routes for the Years 2026 & 2032
    • TABLE 38: Canada Recent Past, Current & Future Analysis for H1N1 Vaccines by Age Group - Pediatric Age Group, Adult Age Group and Geriatric Age Group - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 39: Canada 8-Year Perspective for H1N1 Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group, Adult Age Group and Geriatric Age Group for the Years 2026 & 2032
  • JAPAN
    • H1N1 Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2026 (E)
    • TABLE 40: Japan Recent Past, Current & Future Analysis for H1N1 Vaccines by Product Type - Inactivated Vaccine Product Type and Live Attenuated Vaccine Product Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 41: Japan 8-Year Perspective for H1N1 Vaccines by Product Type - Percentage Breakdown of Value Sales for Inactivated Vaccine Product Type and Live Attenuated Vaccine Product Type for the Years 2026 & 2032
    • TABLE 42: Japan Recent Past, Current & Future Analysis for H1N1 Vaccines by Technology - Egg-based Technology, Cell-based Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 43: Japan 8-Year Perspective for H1N1 Vaccines by Technology - Percentage Breakdown of Value Sales for Egg-based Technology, Cell-based Technology and Other Technologies for the Years 2026 & 2032
    • TABLE 44: Japan Recent Past, Current & Future Analysis for H1N1 Vaccines by Administration Route - Intradermal Administration Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 45: Japan 8-Year Perspective for H1N1 Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intradermal Administration Route and Other Administration Routes for the Years 2026 & 2032
    • TABLE 46: Japan Recent Past, Current & Future Analysis for H1N1 Vaccines by Age Group - Pediatric Age Group, Adult Age Group and Geriatric Age Group - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 47: Japan 8-Year Perspective for H1N1 Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group, Adult Age Group and Geriatric Age Group for the Years 2026 & 2032
  • CHINA
    • H1N1 Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2026 (E)
    • TABLE 48: China Recent Past, Current & Future Analysis for H1N1 Vaccines by Product Type - Inactivated Vaccine Product Type and Live Attenuated Vaccine Product Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 49: China 8-Year Perspective for H1N1 Vaccines by Product Type - Percentage Breakdown of Value Sales for Inactivated Vaccine Product Type and Live Attenuated Vaccine Product Type for the Years 2026 & 2032
    • TABLE 50: China Recent Past, Current & Future Analysis for H1N1 Vaccines by Technology - Egg-based Technology, Cell-based Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 51: China 8-Year Perspective for H1N1 Vaccines by Technology - Percentage Breakdown of Value Sales for Egg-based Technology, Cell-based Technology and Other Technologies for the Years 2026 & 2032
    • TABLE 52: China Recent Past, Current & Future Analysis for H1N1 Vaccines by Administration Route - Intradermal Administration Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 53: China 8-Year Perspective for H1N1 Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intradermal Administration Route and Other Administration Routes for the Years 2026 & 2032
    • TABLE 54: China Recent Past, Current & Future Analysis for H1N1 Vaccines by Age Group - Pediatric Age Group, Adult Age Group and Geriatric Age Group - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 55: China 8-Year Perspective for H1N1 Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group, Adult Age Group and Geriatric Age Group for the Years 2026 & 2032
  • EUROPE
    • H1N1 Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2026 (E)
    • TABLE 56: Europe Recent Past, Current & Future Analysis for H1N1 Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
    • TABLE 57: Europe 8-Year Perspective for H1N1 Vaccines by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2026 & 2032
    • TABLE 58: Europe Recent Past, Current & Future Analysis for H1N1 Vaccines by Product Type - Inactivated Vaccine Product Type and Live Attenuated Vaccine Product Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 59: Europe 8-Year Perspective for H1N1 Vaccines by Product Type - Percentage Breakdown of Value Sales for Inactivated Vaccine Product Type and Live Attenuated Vaccine Product Type for the Years 2026 & 2032
    • TABLE 60: Europe Recent Past, Current & Future Analysis for H1N1 Vaccines by Technology - Egg-based Technology, Cell-based Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 61: Europe 8-Year Perspective for H1N1 Vaccines by Technology - Percentage Breakdown of Value Sales for Egg-based Technology, Cell-based Technology and Other Technologies for the Years 2026 & 2032
    • TABLE 62: Europe Recent Past, Current & Future Analysis for H1N1 Vaccines by Administration Route - Intradermal Administration Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 63: Europe 8-Year Perspective for H1N1 Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intradermal Administration Route and Other Administration Routes for the Years 2026 & 2032
    • TABLE 64: Europe Recent Past, Current & Future Analysis for H1N1 Vaccines by Age Group - Pediatric Age Group, Adult Age Group and Geriatric Age Group - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 65: Europe 8-Year Perspective for H1N1 Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group, Adult Age Group and Geriatric Age Group for the Years 2026 & 2032
  • FRANCE
    • H1N1 Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2026 (E)
    • TABLE 66: France Recent Past, Current & Future Analysis for H1N1 Vaccines by Product Type - Inactivated Vaccine Product Type and Live Attenuated Vaccine Product Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 67: France 8-Year Perspective for H1N1 Vaccines by Product Type - Percentage Breakdown of Value Sales for Inactivated Vaccine Product Type and Live Attenuated Vaccine Product Type for the Years 2026 & 2032
    • TABLE 68: France Recent Past, Current & Future Analysis for H1N1 Vaccines by Technology - Egg-based Technology, Cell-based Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 69: France 8-Year Perspective for H1N1 Vaccines by Technology - Percentage Breakdown of Value Sales for Egg-based Technology, Cell-based Technology and Other Technologies for the Years 2026 & 2032
    • TABLE 70: France Recent Past, Current & Future Analysis for H1N1 Vaccines by Administration Route - Intradermal Administration Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 71: France 8-Year Perspective for H1N1 Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intradermal Administration Route and Other Administration Routes for the Years 2026 & 2032
    • TABLE 72: France Recent Past, Current & Future Analysis for H1N1 Vaccines by Age Group - Pediatric Age Group, Adult Age Group and Geriatric Age Group - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 73: France 8-Year Perspective for H1N1 Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group, Adult Age Group and Geriatric Age Group for the Years 2026 & 2032
  • GERMANY
    • H1N1 Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2026 (E)
    • TABLE 74: Germany Recent Past, Current & Future Analysis for H1N1 Vaccines by Product Type - Inactivated Vaccine Product Type and Live Attenuated Vaccine Product Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 75: Germany 8-Year Perspective for H1N1 Vaccines by Product Type - Percentage Breakdown of Value Sales for Inactivated Vaccine Product Type and Live Attenuated Vaccine Product Type for the Years 2026 & 2032
    • TABLE 76: Germany Recent Past, Current & Future Analysis for H1N1 Vaccines by Technology - Egg-based Technology, Cell-based Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 77: Germany 8-Year Perspective for H1N1 Vaccines by Technology - Percentage Breakdown of Value Sales for Egg-based Technology, Cell-based Technology and Other Technologies for the Years 2026 & 2032
    • TABLE 78: Germany Recent Past, Current & Future Analysis for H1N1 Vaccines by Administration Route - Intradermal Administration Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 79: Germany 8-Year Perspective for H1N1 Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intradermal Administration Route and Other Administration Routes for the Years 2026 & 2032
    • TABLE 80: Germany Recent Past, Current & Future Analysis for H1N1 Vaccines by Age Group - Pediatric Age Group, Adult Age Group and Geriatric Age Group - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 81: Germany 8-Year Perspective for H1N1 Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group, Adult Age Group and Geriatric Age Group for the Years 2026 & 2032
  • ITALY
    • TABLE 82: Italy Recent Past, Current & Future Analysis for H1N1 Vaccines by Product Type - Inactivated Vaccine Product Type and Live Attenuated Vaccine Product Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 83: Italy 8-Year Perspective for H1N1 Vaccines by Product Type - Percentage Breakdown of Value Sales for Inactivated Vaccine Product Type and Live Attenuated Vaccine Product Type for the Years 2026 & 2032
    • TABLE 84: Italy Recent Past, Current & Future Analysis for H1N1 Vaccines by Technology - Egg-based Technology, Cell-based Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 85: Italy 8-Year Perspective for H1N1 Vaccines by Technology - Percentage Breakdown of Value Sales for Egg-based Technology, Cell-based Technology and Other Technologies for the Years 2026 & 2032
    • TABLE 86: Italy Recent Past, Current & Future Analysis for H1N1 Vaccines by Administration Route - Intradermal Administration Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 87: Italy 8-Year Perspective for H1N1 Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intradermal Administration Route and Other Administration Routes for the Years 2026 & 2032
    • TABLE 88: Italy Recent Past, Current & Future Analysis for H1N1 Vaccines by Age Group - Pediatric Age Group, Adult Age Group and Geriatric Age Group - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 89: Italy 8-Year Perspective for H1N1 Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group, Adult Age Group and Geriatric Age Group for the Years 2026 & 2032
  • UNITED KINGDOM
    • H1N1 Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2026 (E)
    • TABLE 90: UK Recent Past, Current & Future Analysis for H1N1 Vaccines by Product Type - Inactivated Vaccine Product Type and Live Attenuated Vaccine Product Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 91: UK 8-Year Perspective for H1N1 Vaccines by Product Type - Percentage Breakdown of Value Sales for Inactivated Vaccine Product Type and Live Attenuated Vaccine Product Type for the Years 2026 & 2032
    • TABLE 92: UK Recent Past, Current & Future Analysis for H1N1 Vaccines by Technology - Egg-based Technology, Cell-based Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 93: UK 8-Year Perspective for H1N1 Vaccines by Technology - Percentage Breakdown of Value Sales for Egg-based Technology, Cell-based Technology and Other Technologies for the Years 2026 & 2032
    • TABLE 94: UK Recent Past, Current & Future Analysis for H1N1 Vaccines by Administration Route - Intradermal Administration Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 95: UK 8-Year Perspective for H1N1 Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intradermal Administration Route and Other Administration Routes for the Years 2026 & 2032
    • TABLE 96: UK Recent Past, Current & Future Analysis for H1N1 Vaccines by Age Group - Pediatric Age Group, Adult Age Group and Geriatric Age Group - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 97: UK 8-Year Perspective for H1N1 Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group, Adult Age Group and Geriatric Age Group for the Years 2026 & 2032
  • SPAIN
    • TABLE 98: Spain Recent Past, Current & Future Analysis for H1N1 Vaccines by Product Type - Inactivated Vaccine Product Type and Live Attenuated Vaccine Product Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 99: Spain 8-Year Perspective for H1N1 Vaccines by Product Type - Percentage Breakdown of Value Sales for Inactivated Vaccine Product Type and Live Attenuated Vaccine Product Type for the Years 2026 & 2032
    • TABLE 100: Spain Recent Past, Current & Future Analysis for H1N1 Vaccines by Technology - Egg-based Technology, Cell-based Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 101: Spain 8-Year Perspective for H1N1 Vaccines by Technology - Percentage Breakdown of Value Sales for Egg-based Technology, Cell-based Technology and Other Technologies for the Years 2026 & 2032
    • TABLE 102: Spain Recent Past, Current & Future Analysis for H1N1 Vaccines by Administration Route - Intradermal Administration Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 103: Spain 8-Year Perspective for H1N1 Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intradermal Administration Route and Other Administration Routes for the Years 2026 & 2032
    • TABLE 104: Spain Recent Past, Current & Future Analysis for H1N1 Vaccines by Age Group - Pediatric Age Group, Adult Age Group and Geriatric Age Group - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 105: Spain 8-Year Perspective for H1N1 Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group, Adult Age Group and Geriatric Age Group for the Years 2026 & 2032
  • RUSSIA
    • TABLE 106: Russia Recent Past, Current & Future Analysis for H1N1 Vaccines by Product Type - Inactivated Vaccine Product Type and Live Attenuated Vaccine Product Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 107: Russia 8-Year Perspective for H1N1 Vaccines by Product Type - Percentage Breakdown of Value Sales for Inactivated Vaccine Product Type and Live Attenuated Vaccine Product Type for the Years 2026 & 2032
    • TABLE 108: Russia Recent Past, Current & Future Analysis for H1N1 Vaccines by Technology - Egg-based Technology, Cell-based Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 109: Russia 8-Year Perspective for H1N1 Vaccines by Technology - Percentage Breakdown of Value Sales for Egg-based Technology, Cell-based Technology and Other Technologies for the Years 2026 & 2032
    • TABLE 110: Russia Recent Past, Current & Future Analysis for H1N1 Vaccines by Administration Route - Intradermal Administration Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 111: Russia 8-Year Perspective for H1N1 Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intradermal Administration Route and Other Administration Routes for the Years 2026 & 2032
    • TABLE 112: Russia Recent Past, Current & Future Analysis for H1N1 Vaccines by Age Group - Pediatric Age Group, Adult Age Group and Geriatric Age Group - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 113: Russia 8-Year Perspective for H1N1 Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group, Adult Age Group and Geriatric Age Group for the Years 2026 & 2032
  • REST OF EUROPE
    • TABLE 114: Rest of Europe Recent Past, Current & Future Analysis for H1N1 Vaccines by Product Type - Inactivated Vaccine Product Type and Live Attenuated Vaccine Product Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 115: Rest of Europe 8-Year Perspective for H1N1 Vaccines by Product Type - Percentage Breakdown of Value Sales for Inactivated Vaccine Product Type and Live Attenuated Vaccine Product Type for the Years 2026 & 2032
    • TABLE 116: Rest of Europe Recent Past, Current & Future Analysis for H1N1 Vaccines by Technology - Egg-based Technology, Cell-based Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 117: Rest of Europe 8-Year Perspective for H1N1 Vaccines by Technology - Percentage Breakdown of Value Sales for Egg-based Technology, Cell-based Technology and Other Technologies for the Years 2026 & 2032
    • TABLE 118: Rest of Europe Recent Past, Current & Future Analysis for H1N1 Vaccines by Administration Route - Intradermal Administration Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 119: Rest of Europe 8-Year Perspective for H1N1 Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intradermal Administration Route and Other Administration Routes for the Years 2026 & 2032
    • TABLE 120: Rest of Europe Recent Past, Current & Future Analysis for H1N1 Vaccines by Age Group - Pediatric Age Group, Adult Age Group and Geriatric Age Group - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 121: Rest of Europe 8-Year Perspective for H1N1 Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group, Adult Age Group and Geriatric Age Group for the Years 2026 & 2032
  • ASIA-PACIFIC
    • H1N1 Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2026 (E)
    • TABLE 122: Asia-Pacific Recent Past, Current & Future Analysis for H1N1 Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
    • TABLE 123: Asia-Pacific 8-Year Perspective for H1N1 Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2026 & 2032
    • TABLE 124: Asia-Pacific Recent Past, Current & Future Analysis for H1N1 Vaccines by Product Type - Inactivated Vaccine Product Type and Live Attenuated Vaccine Product Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 125: Asia-Pacific 8-Year Perspective for H1N1 Vaccines by Product Type - Percentage Breakdown of Value Sales for Inactivated Vaccine Product Type and Live Attenuated Vaccine Product Type for the Years 2026 & 2032
    • TABLE 126: Asia-Pacific Recent Past, Current & Future Analysis for H1N1 Vaccines by Technology - Egg-based Technology, Cell-based Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 127: Asia-Pacific 8-Year Perspective for H1N1 Vaccines by Technology - Percentage Breakdown of Value Sales for Egg-based Technology, Cell-based Technology and Other Technologies for the Years 2026 & 2032
    • TABLE 128: Asia-Pacific Recent Past, Current & Future Analysis for H1N1 Vaccines by Administration Route - Intradermal Administration Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 129: Asia-Pacific 8-Year Perspective for H1N1 Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intradermal Administration Route and Other Administration Routes for the Years 2026 & 2032
    • TABLE 130: Asia-Pacific Recent Past, Current & Future Analysis for H1N1 Vaccines by Age Group - Pediatric Age Group, Adult Age Group and Geriatric Age Group - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 131: Asia-Pacific 8-Year Perspective for H1N1 Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group, Adult Age Group and Geriatric Age Group for the Years 2026 & 2032
  • AUSTRALIA
    • H1N1 Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2026 (E)
    • TABLE 132: Australia Recent Past, Current & Future Analysis for H1N1 Vaccines by Product Type - Inactivated Vaccine Product Type and Live Attenuated Vaccine Product Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 133: Australia 8-Year Perspective for H1N1 Vaccines by Product Type - Percentage Breakdown of Value Sales for Inactivated Vaccine Product Type and Live Attenuated Vaccine Product Type for the Years 2026 & 2032
    • TABLE 134: Australia Recent Past, Current & Future Analysis for H1N1 Vaccines by Technology - Egg-based Technology, Cell-based Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 135: Australia 8-Year Perspective for H1N1 Vaccines by Technology - Percentage Breakdown of Value Sales for Egg-based Technology, Cell-based Technology and Other Technologies for the Years 2026 & 2032
    • TABLE 136: Australia Recent Past, Current & Future Analysis for H1N1 Vaccines by Administration Route - Intradermal Administration Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 137: Australia 8-Year Perspective for H1N1 Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intradermal Administration Route and Other Administration Routes for the Years 2026 & 2032
    • TABLE 138: Australia Recent Past, Current & Future Analysis for H1N1 Vaccines by Age Group - Pediatric Age Group, Adult Age Group and Geriatric Age Group - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 139: Australia 8-Year Perspective for H1N1 Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group, Adult Age Group and Geriatric Age Group for the Years 2026 & 2032
  • INDIA
    • H1N1 Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2026 (E)
    • TABLE 140: India Recent Past, Current & Future Analysis for H1N1 Vaccines by Product Type - Inactivated Vaccine Product Type and Live Attenuated Vaccine Product Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 141: India 8-Year Perspective for H1N1 Vaccines by Product Type - Percentage Breakdown of Value Sales for Inactivated Vaccine Product Type and Live Attenuated Vaccine Product Type for the Years 2026 & 2032
    • TABLE 142: India Recent Past, Current & Future Analysis for H1N1 Vaccines by Technology - Egg-based Technology, Cell-based Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 143: India 8-Year Perspective for H1N1 Vaccines by Technology - Percentage Breakdown of Value Sales for Egg-based Technology, Cell-based Technology and Other Technologies for the Years 2026 & 2032
    • TABLE 144: India Recent Past, Current & Future Analysis for H1N1 Vaccines by Administration Route - Intradermal Administration Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 145: India 8-Year Perspective for H1N1 Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intradermal Administration Route and Other Administration Routes for the Years 2026 & 2032
    • TABLE 146: India Recent Past, Current & Future Analysis for H1N1 Vaccines by Age Group - Pediatric Age Group, Adult Age Group and Geriatric Age Group - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 147: India 8-Year Perspective for H1N1 Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group, Adult Age Group and Geriatric Age Group for the Years 2026 & 2032
  • SOUTH KOREA
    • TABLE 148: South Korea Recent Past, Current & Future Analysis for H1N1 Vaccines by Product Type - Inactivated Vaccine Product Type and Live Attenuated Vaccine Product Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 149: South Korea 8-Year Perspective for H1N1 Vaccines by Product Type - Percentage Breakdown of Value Sales for Inactivated Vaccine Product Type and Live Attenuated Vaccine Product Type for the Years 2026 & 2032
    • TABLE 150: South Korea Recent Past, Current & Future Analysis for H1N1 Vaccines by Technology - Egg-based Technology, Cell-based Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 151: South Korea 8-Year Perspective for H1N1 Vaccines by Technology - Percentage Breakdown of Value Sales for Egg-based Technology, Cell-based Technology and Other Technologies for the Years 2026 & 2032
    • TABLE 152: South Korea Recent Past, Current & Future Analysis for H1N1 Vaccines by Administration Route - Intradermal Administration Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 153: South Korea 8-Year Perspective for H1N1 Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intradermal Administration Route and Other Administration Routes for the Years 2026 & 2032
    • TABLE 154: South Korea Recent Past, Current & Future Analysis for H1N1 Vaccines by Age Group - Pediatric Age Group, Adult Age Group and Geriatric Age Group - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 155: South Korea 8-Year Perspective for H1N1 Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group, Adult Age Group and Geriatric Age Group for the Years 2026 & 2032
  • REST OF ASIA-PACIFIC
    • TABLE 156: Rest of Asia-Pacific Recent Past, Current & Future Analysis for H1N1 Vaccines by Product Type - Inactivated Vaccine Product Type and Live Attenuated Vaccine Product Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 157: Rest of Asia-Pacific 8-Year Perspective for H1N1 Vaccines by Product Type - Percentage Breakdown of Value Sales for Inactivated Vaccine Product Type and Live Attenuated Vaccine Product Type for the Years 2026 & 2032
    • TABLE 158: Rest of Asia-Pacific Recent Past, Current & Future Analysis for H1N1 Vaccines by Technology - Egg-based Technology, Cell-based Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 159: Rest of Asia-Pacific 8-Year Perspective for H1N1 Vaccines by Technology - Percentage Breakdown of Value Sales for Egg-based Technology, Cell-based Technology and Other Technologies for the Years 2026 & 2032
    • TABLE 160: Rest of Asia-Pacific Recent Past, Current & Future Analysis for H1N1 Vaccines by Administration Route - Intradermal Administration Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 161: Rest of Asia-Pacific 8-Year Perspective for H1N1 Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intradermal Administration Route and Other Administration Routes for the Years 2026 & 2032
    • TABLE 162: Rest of Asia-Pacific Recent Past, Current & Future Analysis for H1N1 Vaccines by Age Group - Pediatric Age Group, Adult Age Group and Geriatric Age Group - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 163: Rest of Asia-Pacific 8-Year Perspective for H1N1 Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group, Adult Age Group and Geriatric Age Group for the Years 2026 & 2032
  • LATIN AMERICA
    • H1N1 Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2026 (E)
    • TABLE 164: Latin America Recent Past, Current & Future Analysis for H1N1 Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
    • TABLE 165: Latin America 8-Year Perspective for H1N1 Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2026 & 2032
    • TABLE 166: Latin America Recent Past, Current & Future Analysis for H1N1 Vaccines by Product Type - Inactivated Vaccine Product Type and Live Attenuated Vaccine Product Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 167: Latin America 8-Year Perspective for H1N1 Vaccines by Product Type - Percentage Breakdown of Value Sales for Inactivated Vaccine Product Type and Live Attenuated Vaccine Product Type for the Years 2026 & 2032
    • TABLE 168: Latin America Recent Past, Current & Future Analysis for H1N1 Vaccines by Technology - Egg-based Technology, Cell-based Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 169: Latin America 8-Year Perspective for H1N1 Vaccines by Technology - Percentage Breakdown of Value Sales for Egg-based Technology, Cell-based Technology and Other Technologies for the Years 2026 & 2032
    • TABLE 170: Latin America Recent Past, Current & Future Analysis for H1N1 Vaccines by Administration Route - Intradermal Administration Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 171: Latin America 8-Year Perspective for H1N1 Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intradermal Administration Route and Other Administration Routes for the Years 2026 & 2032
    • TABLE 172: Latin America Recent Past, Current & Future Analysis for H1N1 Vaccines by Age Group - Pediatric Age Group, Adult Age Group and Geriatric Age Group - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 173: Latin America 8-Year Perspective for H1N1 Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group, Adult Age Group and Geriatric Age Group for the Years 2026 & 2032
  • ARGENTINA
    • TABLE 174: Argentina Recent Past, Current & Future Analysis for H1N1 Vaccines by Product Type - Inactivated Vaccine Product Type and Live Attenuated Vaccine Product Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 175: Argentina 8-Year Perspective for H1N1 Vaccines by Product Type - Percentage Breakdown of Value Sales for Inactivated Vaccine Product Type and Live Attenuated Vaccine Product Type for the Years 2026 & 2032
    • TABLE 176: Argentina Recent Past, Current & Future Analysis for H1N1 Vaccines by Technology - Egg-based Technology, Cell-based Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 177: Argentina 8-Year Perspective for H1N1 Vaccines by Technology - Percentage Breakdown of Value Sales for Egg-based Technology, Cell-based Technology and Other Technologies for the Years 2026 & 2032
    • TABLE 178: Argentina Recent Past, Current & Future Analysis for H1N1 Vaccines by Administration Route - Intradermal Administration Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 179: Argentina 8-Year Perspective for H1N1 Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intradermal Administration Route and Other Administration Routes for the Years 2026 & 2032
    • TABLE 180: Argentina Recent Past, Current & Future Analysis for H1N1 Vaccines by Age Group - Pediatric Age Group, Adult Age Group and Geriatric Age Group - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 181: Argentina 8-Year Perspective for H1N1 Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group, Adult Age Group and Geriatric Age Group for the Years 2026 & 2032
  • BRAZIL
    • TABLE 182: Brazil Recent Past, Current & Future Analysis for H1N1 Vaccines by Product Type - Inactivated Vaccine Product Type and Live Attenuated Vaccine Product Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 183: Brazil 8-Year Perspective for H1N1 Vaccines by Product Type - Percentage Breakdown of Value Sales for Inactivated Vaccine Product Type and Live Attenuated Vaccine Product Type for the Years 2026 & 2032
    • TABLE 184: Brazil Recent Past, Current & Future Analysis for H1N1 Vaccines by Technology - Egg-based Technology, Cell-based Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 185: Brazil 8-Year Perspective for H1N1 Vaccines by Technology - Percentage Breakdown of Value Sales for Egg-based Technology, Cell-based Technology and Other Technologies for the Years 2026 & 2032
    • TABLE 186: Brazil Recent Past, Current & Future Analysis for H1N1 Vaccines by Administration Route - Intradermal Administration Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 187: Brazil 8-Year Perspective for H1N1 Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intradermal Administration Route and Other Administration Routes for the Years 2026 & 2032
    • TABLE 188: Brazil Recent Past, Current & Future Analysis for H1N1 Vaccines by Age Group - Pediatric Age Group, Adult Age Group and Geriatric Age Group - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 189: Brazil 8-Year Perspective for H1N1 Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group, Adult Age Group and Geriatric Age Group for the Years 2026 & 2032
  • MEXICO
    • TABLE 190: Mexico Recent Past, Current & Future Analysis for H1N1 Vaccines by Product Type - Inactivated Vaccine Product Type and Live Attenuated Vaccine Product Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 191: Mexico 8-Year Perspective for H1N1 Vaccines by Product Type - Percentage Breakdown of Value Sales for Inactivated Vaccine Product Type and Live Attenuated Vaccine Product Type for the Years 2026 & 2032
    • TABLE 192: Mexico Recent Past, Current & Future Analysis for H1N1 Vaccines by Technology - Egg-based Technology, Cell-based Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 193: Mexico 8-Year Perspective for H1N1 Vaccines by Technology - Percentage Breakdown of Value Sales for Egg-based Technology, Cell-based Technology and Other Technologies for the Years 2026 & 2032
    • TABLE 194: Mexico Recent Past, Current & Future Analysis for H1N1 Vaccines by Administration Route - Intradermal Administration Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 195: Mexico 8-Year Perspective for H1N1 Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intradermal Administration Route and Other Administration Routes for the Years 2026 & 2032
    • TABLE 196: Mexico Recent Past, Current & Future Analysis for H1N1 Vaccines by Age Group - Pediatric Age Group, Adult Age Group and Geriatric Age Group - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 197: Mexico 8-Year Perspective for H1N1 Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group, Adult Age Group and Geriatric Age Group for the Years 2026 & 2032
  • REST OF LATIN AMERICA
    • TABLE 198: Rest of Latin America Recent Past, Current & Future Analysis for H1N1 Vaccines by Product Type - Inactivated Vaccine Product Type and Live Attenuated Vaccine Product Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 199: Rest of Latin America 8-Year Perspective for H1N1 Vaccines by Product Type - Percentage Breakdown of Value Sales for Inactivated Vaccine Product Type and Live Attenuated Vaccine Product Type for the Years 2026 & 2032
    • TABLE 200: Rest of Latin America Recent Past, Current & Future Analysis for H1N1 Vaccines by Technology - Egg-based Technology, Cell-based Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 201: Rest of Latin America 8-Year Perspective for H1N1 Vaccines by Technology - Percentage Breakdown of Value Sales for Egg-based Technology, Cell-based Technology and Other Technologies for the Years 2026 & 2032
    • TABLE 202: Rest of Latin America Recent Past, Current & Future Analysis for H1N1 Vaccines by Administration Route - Intradermal Administration Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 203: Rest of Latin America 8-Year Perspective for H1N1 Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intradermal Administration Route and Other Administration Routes for the Years 2026 & 2032
    • TABLE 204: Rest of Latin America Recent Past, Current & Future Analysis for H1N1 Vaccines by Age Group - Pediatric Age Group, Adult Age Group and Geriatric Age Group - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 205: Rest of Latin America 8-Year Perspective for H1N1 Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group, Adult Age Group and Geriatric Age Group for the Years 2026 & 2032
  • MIDDLE EAST
    • H1N1 Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2026 (E)
    • TABLE 206: Middle East Recent Past, Current & Future Analysis for H1N1 Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
    • TABLE 207: Middle East 8-Year Perspective for H1N1 Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2026 & 2032
    • TABLE 208: Middle East Recent Past, Current & Future Analysis for H1N1 Vaccines by Product Type - Inactivated Vaccine Product Type and Live Attenuated Vaccine Product Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 209: Middle East 8-Year Perspective for H1N1 Vaccines by Product Type - Percentage Breakdown of Value Sales for Inactivated Vaccine Product Type and Live Attenuated Vaccine Product Type for the Years 2026 & 2032
    • TABLE 210: Middle East Recent Past, Current & Future Analysis for H1N1 Vaccines by Technology - Egg-based Technology, Cell-based Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 211: Middle East 8-Year Perspective for H1N1 Vaccines by Technology - Percentage Breakdown of Value Sales for Egg-based Technology, Cell-based Technology and Other Technologies for the Years 2026 & 2032
    • TABLE 212: Middle East Recent Past, Current & Future Analysis for H1N1 Vaccines by Administration Route - Intradermal Administration Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 213: Middle East 8-Year Perspective for H1N1 Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intradermal Administration Route and Other Administration Routes for the Years 2026 & 2032
    • TABLE 214: Middle East Recent Past, Current & Future Analysis for H1N1 Vaccines by Age Group - Pediatric Age Group, Adult Age Group and Geriatric Age Group - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 215: Middle East 8-Year Perspective for H1N1 Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group, Adult Age Group and Geriatric Age Group for the Years 2026 & 2032
  • IRAN
    • TABLE 216: Iran Recent Past, Current & Future Analysis for H1N1 Vaccines by Product Type - Inactivated Vaccine Product Type and Live Attenuated Vaccine Product Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 217: Iran 8-Year Perspective for H1N1 Vaccines by Product Type - Percentage Breakdown of Value Sales for Inactivated Vaccine Product Type and Live Attenuated Vaccine Product Type for the Years 2026 & 2032
    • TABLE 218: Iran Recent Past, Current & Future Analysis for H1N1 Vaccines by Technology - Egg-based Technology, Cell-based Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 219: Iran 8-Year Perspective for H1N1 Vaccines by Technology - Percentage Breakdown of Value Sales for Egg-based Technology, Cell-based Technology and Other Technologies for the Years 2026 & 2032
    • TABLE 220: Iran Recent Past, Current & Future Analysis for H1N1 Vaccines by Administration Route - Intradermal Administration Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 221: Iran 8-Year Perspective for H1N1 Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intradermal Administration Route and Other Administration Routes for the Years 2026 & 2032
    • TABLE 222: Iran Recent Past, Current & Future Analysis for H1N1 Vaccines by Age Group - Pediatric Age Group, Adult Age Group and Geriatric Age Group - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 223: Iran 8-Year Perspective for H1N1 Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group, Adult Age Group and Geriatric Age Group for the Years 2026 & 2032
  • ISRAEL
    • TABLE 224: Israel Recent Past, Current & Future Analysis for H1N1 Vaccines by Product Type - Inactivated Vaccine Product Type and Live Attenuated Vaccine Product Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 225: Israel 8-Year Perspective for H1N1 Vaccines by Product Type - Percentage Breakdown of Value Sales for Inactivated Vaccine Product Type and Live Attenuated Vaccine Product Type for the Years 2026 & 2032
    • TABLE 226: Israel Recent Past, Current & Future Analysis for H1N1 Vaccines by Technology - Egg-based Technology, Cell-based Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 227: Israel 8-Year Perspective for H1N1 Vaccines by Technology - Percentage Breakdown of Value Sales for Egg-based Technology, Cell-based Technology and Other Technologies for the Years 2026 & 2032
    • TABLE 228: Israel Recent Past, Current & Future Analysis for H1N1 Vaccines by Administration Route - Intradermal Administration Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 229: Israel 8-Year Perspective for H1N1 Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intradermal Administration Route and Other Administration Routes for the Years 2026 & 2032
    • TABLE 230: Israel Recent Past, Current & Future Analysis for H1N1 Vaccines by Age Group - Pediatric Age Group, Adult Age Group and Geriatric Age Group - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 231: Israel 8-Year Perspective for H1N1 Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group, Adult Age Group and Geriatric Age Group for the Years 2026 & 2032
  • SAUDI ARABIA
    • TABLE 232: Saudi Arabia Recent Past, Current & Future Analysis for H1N1 Vaccines by Product Type - Inactivated Vaccine Product Type and Live Attenuated Vaccine Product Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 233: Saudi Arabia 8-Year Perspective for H1N1 Vaccines by Product Type - Percentage Breakdown of Value Sales for Inactivated Vaccine Product Type and Live Attenuated Vaccine Product Type for the Years 2026 & 2032
    • TABLE 234: Saudi Arabia Recent Past, Current & Future Analysis for H1N1 Vaccines by Technology - Egg-based Technology, Cell-based Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 235: Saudi Arabia 8-Year Perspective for H1N1 Vaccines by Technology - Percentage Breakdown of Value Sales for Egg-based Technology, Cell-based Technology and Other Technologies for the Years 2026 & 2032
    • TABLE 236: Saudi Arabia Recent Past, Current & Future Analysis for H1N1 Vaccines by Administration Route - Intradermal Administration Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 237: Saudi Arabia 8-Year Perspective for H1N1 Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intradermal Administration Route and Other Administration Routes for the Years 2026 & 2032
    • TABLE 238: Saudi Arabia Recent Past, Current & Future Analysis for H1N1 Vaccines by Age Group - Pediatric Age Group, Adult Age Group and Geriatric Age Group - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 239: Saudi Arabia 8-Year Perspective for H1N1 Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group, Adult Age Group and Geriatric Age Group for the Years 2026 & 2032
  • UNITED ARAB EMIRATES
    • TABLE 240: UAE Recent Past, Current & Future Analysis for H1N1 Vaccines by Product Type - Inactivated Vaccine Product Type and Live Attenuated Vaccine Product Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 241: UAE 8-Year Perspective for H1N1 Vaccines by Product Type - Percentage Breakdown of Value Sales for Inactivated Vaccine Product Type and Live Attenuated Vaccine Product Type for the Years 2026 & 2032
    • TABLE 242: UAE Recent Past, Current & Future Analysis for H1N1 Vaccines by Technology - Egg-based Technology, Cell-based Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 243: UAE 8-Year Perspective for H1N1 Vaccines by Technology - Percentage Breakdown of Value Sales for Egg-based Technology, Cell-based Technology and Other Technologies for the Years 2026 & 2032
    • TABLE 244: UAE Recent Past, Current & Future Analysis for H1N1 Vaccines by Administration Route - Intradermal Administration Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 245: UAE 8-Year Perspective for H1N1 Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intradermal Administration Route and Other Administration Routes for the Years 2026 & 2032
    • TABLE 246: UAE Recent Past, Current & Future Analysis for H1N1 Vaccines by Age Group - Pediatric Age Group, Adult Age Group and Geriatric Age Group - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 247: UAE 8-Year Perspective for H1N1 Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group, Adult Age Group and Geriatric Age Group for the Years 2026 & 2032
  • REST OF MIDDLE EAST
    • TABLE 248: Rest of Middle East Recent Past, Current & Future Analysis for H1N1 Vaccines by Product Type - Inactivated Vaccine Product Type and Live Attenuated Vaccine Product Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 249: Rest of Middle East 8-Year Perspective for H1N1 Vaccines by Product Type - Percentage Breakdown of Value Sales for Inactivated Vaccine Product Type and Live Attenuated Vaccine Product Type for the Years 2026 & 2032
    • TABLE 250: Rest of Middle East Recent Past, Current & Future Analysis for H1N1 Vaccines by Technology - Egg-based Technology, Cell-based Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 251: Rest of Middle East 8-Year Perspective for H1N1 Vaccines by Technology - Percentage Breakdown of Value Sales for Egg-based Technology, Cell-based Technology and Other Technologies for the Years 2026 & 2032
    • TABLE 252: Rest of Middle East Recent Past, Current & Future Analysis for H1N1 Vaccines by Administration Route - Intradermal Administration Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 253: Rest of Middle East 8-Year Perspective for H1N1 Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intradermal Administration Route and Other Administration Routes for the Years 2026 & 2032
    • TABLE 254: Rest of Middle East Recent Past, Current & Future Analysis for H1N1 Vaccines by Age Group - Pediatric Age Group, Adult Age Group and Geriatric Age Group - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 255: Rest of Middle East 8-Year Perspective for H1N1 Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group, Adult Age Group and Geriatric Age Group for the Years 2026 & 2032
  • AFRICA
    • H1N1 Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2026 (E)
    • TABLE 256: Africa Recent Past, Current & Future Analysis for H1N1 Vaccines by Product Type - Inactivated Vaccine Product Type and Live Attenuated Vaccine Product Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 257: Africa 8-Year Perspective for H1N1 Vaccines by Product Type - Percentage Breakdown of Value Sales for Inactivated Vaccine Product Type and Live Attenuated Vaccine Product Type for the Years 2026 & 2032
    • TABLE 258: Africa Recent Past, Current & Future Analysis for H1N1 Vaccines by Technology - Egg-based Technology, Cell-based Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 259: Africa 8-Year Perspective for H1N1 Vaccines by Technology - Percentage Breakdown of Value Sales for Egg-based Technology, Cell-based Technology and Other Technologies for the Years 2026 & 2032
    • TABLE 260: Africa Recent Past, Current & Future Analysis for H1N1 Vaccines by Administration Route - Intradermal Administration Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 261: Africa 8-Year Perspective for H1N1 Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intradermal Administration Route and Other Administration Routes for the Years 2026 & 2032
    • TABLE 262: Africa Recent Past, Current & Future Analysis for H1N1 Vaccines by Age Group - Pediatric Age Group, Adult Age Group and Geriatric Age Group - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 263: Africa 8-Year Perspective for H1N1 Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group, Adult Age Group and Geriatric Age Group for the Years 2026 & 2032

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!